PARP Inhibitors in the Management of Ovarian Cancer
Key Points
Key Points
- These recommendations pertain only to patients with epithelial ovarian, tubal, or primary peritoneal cancer who have not previously received a poly(ADP-ribose) polymerase inhibitors (PARPi).
- The recommendations are based on clinical trial results and FDA approvals and do not necessarily capture regulatory approvals in other jurisdictions.
Treatment
...atment...
...epeating PARPi...
Recommendation 1.0Repeating PARPi therapy in the...
Newly Diagnosed Ovarian Ca...
...endation 2.0PARPi are NOT recommended for...
...pid Update – Recommendation 2.1Patients w...
...ommendation 2.2The addition of olaparib to beva...
...endation 2.3Inclusion of the PARPi, veliparib, wit...
...rian Cancer - Second-line or Greater Maintenan...
...ate – Recommendation 3.0
...rapy maintenance (second-line or more) ma...
...enance treatment with niraparib for patients with...
...ate – Recommendation 3.1/3.2PARPi monothe...
Rapid Update – Recommendation 3.3PARPi monothe...
...Pi in Combination...
...ndation 4.0PARPi are NOT recommended for use...
...nt of Adverse Events...
...dation 5.0 Anemia...
...Patients requiring a blood transfu...
...h progressive anemia may be offered...
...mendation 5.1 Neutropenia:
...factor is NOT indicated for use in patients rec...
...utropenia (grade 4 lasting at least 5–7 days o...
...ommendation 5.2 Plate...
...ocytopenia is most common with niraparib. N...
...scontinue PARPi for persistent thrombocyt...
...ndation 5.3 Persistent cytopenia:Evaluation for tr...
...mmendation 5.4 Nausea:...
a. Many patients will have tachyphylaxis of n...
...ent nausea requiring daily anti-emetic interven...
...ble 1. PARP Inhibitors in the Manageme...
...re 1. PARPi Use Opportunities in PARPi-N...